In partnership with

  • Conferences
  • Disease Areas
  • News
  • Articles
  • Contact
    • Highlights from

    European Crohn’s and Colitis Organisation

    Congress 2018

    Vienna 14-17 February 2018

    A total of 6,654 attendees from 86 countries came together for the most important IBD meeting in the world, the 13th edition of the annual congress of the European Crohn’s and Colitis Organisation (ECCO) in Vienna.

    Articles

    Introduction

    article thumbnail

    Letter from The Editor

    IBD diagnostics

    Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines

    IBD disease patterns and genetics

    Quiescent disease, characteristics and biomarker correlations

    ILC1 distribution predicts response to ustekinumab

    Central role of IL-23 in molecular resistance to anti-TNF therapy

    Genetic predisposition for gut barrier dysfunction

    Targeting early disease: lessons from rheumatoid arthritis

    Integration of “omics” and potential for clinical practice

    Novel treatment strategies

    Combining new drugs with different mechanisms

    Cobitolimod induces anti-inflammatory effects by balancing Th17/T-reg cell response

    Apremilast in active UC shows promising results

    Early and significant effects with upadacitinib induction treatment

    Vedolizumab induces endoscopic remission and healing in refractory CD

    SHP647 is efficacious and well-tolerated in CD

    Higher rates of remission and healing with vedolizumab vs. TNF antagonist

    Comparative effectiveness of vedolizumab and ustekinumab in CD

    Efficacy and safety of biologics

    Vedolizumab in anti-TNF-naïve IBD patients and safety profile

    Long-term safety profile of adalimumab

    Overall manageable safety profile of tofacitinib in long-term use

    Oncology in IBD

    Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD

    Cancer risk in IBD associated with age and recent immunomodulator use

    Shallow whole-genome sequencing predicts future cancer risk of LGD in UC

    Malignancies occur infrequently with tofacitinib

    SLC12A2 potential marker of dysplasia associated to inflammation in UC

    Significantly increased risk of CRC and/or HGD after appendectomy in UC

    Surgery for IBD

    Enhanced post-operative recovery pathways for IBD patients

    Higher colectomy rate with infliximab vs. conventional therapies in more severe UC

    Significant reduction of emergency stoma surgeries for CD

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    BACK TO TOP